Table 1.
Main changes in the nutritional status after transjugular intrahepatic portosystemic shunt placement in cirrhotic patients.
| Reference | Design | Sample Size | TIPS Indication | Follow-Up after | Measure | Change |
|---|---|---|---|---|---|---|
| Allard et al. (2001) [27] | - | 14 (71% ♂) | RA (100%) | 12 M | W, Dry W, FM, F10/F30, and MRR | Significant increase in Dry W and FM. |
| Artru et al. (2020) [19] | RS | 179 (72% ♂) | RA (47.5%), VB (52.5%) | 6 M | TPMT, TPMA, SFA, and VFA | Significant increase in TPMT, TPMA, and SFA and significant decrease in VFA. |
| Gioia et al. (2019) [13] | RS | 27 (85% ♂) | RA (56%), VB (44%) | 9.8 M | SMI | Significant increase in SMI. |
| Gioia et al. (2021) [14] | RS | 35 (80% ♂) | RA (54%), VB (46%) | 19 M | SMI, SATI, and VATI | Significant increase in SMI and SATI and significant decrease in VATI. |
| Holland-Fischer et al. (2010) [29] | - | 11 (73% ♂) | RA (64%), RA+VB (36%) | 6 M | W, BMI, BCM, LBM, and FM | Significant increase in all but FM. |
| Holland-Fischer et al. (2009) [28] | - | 17 | RA (59%), VB (29%), both (12%) | 13 M | W and BCM | Significant increase in BCM. |
| Jahangiri et al. (2019) [21] | RS | 76 (56.2% ♂) | RA/RH(52.6%), VB (47.4%) | 13.5 M | SMA | Significant increase in SMA. |
| Liu et al. (2022) [20] | RS | 224 (71% ♂) | RA (14%), VB (86%) | 12 M | SMA, SMI, SFA, SFT, AF W, and AF BMI | No significant change in SMA, SMI, SFA, and SFT in patients without sarcopenia. Significant increase in SMA, SMI, SFA, and SFT in patients with sarcopenia. No significant change in AF W and AF BMI in patients without ascites and sarcopenia. Significant increase in AF W and AF BMI in patients with sarcopenia but without ascites. |
| Montomoli et al. (2010) [26] | PS | 21 | RA (57%), VB (33%), both (10%) | 13 M | BMI, FM, and DLM | No significant change in overweight patients, significant increase in dry lean mass in under/normal weight patients. |
| Nolte et al. (2003) [25] | PS | 31 | RA, VB | 9 M | W, BMI, AF W, and AF BMI | Significant increase in W, BMI, AF W, and AF BMI in male patients, significant increase in AF W and AF BMI in female patients. |
| Pang et al. (2021) [22] | RS | 77 | RA, VB | 13 M | W, BMI | Significant increase in W and BMI. |
| Plauth et al. (2004) [24] | PS | 21 (62% ♂) | RA (33%), VB (43%), both (24%) | 12 M | W, BMI, MAFA, MAMA, and BCM | Significant increase in W, BMI, and MAMA. |
| Thomsen et al. (2012) [30] | - | 25 (60% ♂) | RA (68%), VB (20%), both (12%) | 6 M | W, BMI, FM*, and BCM | Significant increase in BCM. |
| Trotter et al. (1998) [23] | RS | 35 (69% ♂) | RA | 8.8 M | W | Significant increase in W. |
| Tsien et al. (2012) [15] | - | 57 (63% ♂) | RA (72%), VB (25%), both (3%) | 13.5 M | BMI, SMA, VAT, and SAT | Significant increase in SMA and significant decrease in SAT. |
Footnote: AF—ascitic-free, ASC—ascites, BCM—body cell mass (kg), BMI—body mass index (kg/m2), DLM—dry lean mass (kg), FM—fat mass (% of total body weight/*kg), F10/F30—force of m. adductor policis (%), kg—kilogram, M—months, MAFA—mid-arm fat area, MAMA—mid-arm muscle area (cm2), MRR—muscle relaxation rate (m. adductor policis) (%), SAT—subcutaneous adipose tissue (cm3/3 mm), SATI—subcutaneous adipose tissue index (cm2/m2), SFA—subcutaneous fat area (cm2), SFT—subcutaneous fat thickness (cm), SMA—skeletal muscle area (cm2), SMI—skeletal muscle index (cm2/m2), TPMA—total psoas muscle area (mm2), TPMT—transversal right psoas muscle thickness at the umbilical level/height (mm/m), TIPS—transjugular intrahepatic portosystemic shunt, VAT—visceral adipose tissue (cm3/3 mm), VATI—visceral adipose tissue index (cm2/m2), VFA—visceral fat area (cm2), W—weight (kg), -—no information. A more detailed table is provided within the Supplementary Materials.